Chemoproteomics Reveals Novel Protein and Lipid Kinase Targets of Clinical CDK4/6 Inhibitors in Lung Cancer

ACS Chemical Biology - United States
doi 10.1021/acschembio.5b00368
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Chemical Society (ACS)

Related search

A Novel Tankyrase Inhibitor, MSC2504877, Enhances the Effects of Clinical CDK4/6 Inhibitors

Scientific Reports
Multidisciplinary
2019English

Treating ER+ Breast Cancer With CDK4/6 Inhibitors

Cancer Discovery
Oncology
2017English

CDK4/6 Inhibitors: Promising Opportunities Beyond Breast Cancer

Cancer Discovery
Oncology
2016English

CDK4/6 Inhibitors resTORe Therapeutic Sensitivity in HER2 + Breast Cancer

Cancer Cell
Cancer ResearchOncologyCell Biology
2016English

Tyrosine Kinase Inhibitors in Lung Cancer

Hematology/Oncology Clinics of North America
OncologyHematology
2012English

Inhibitors Targeting CDK4/6, PARP and PI3K in Breast Cancer: A Review

Therapeutic Advances in Medical Oncology
Oncology
2018English

Loss of FAT1 Drives Resistance to CDK4/6 Inhibitors in Breast Cancer

Cancer Discovery
Oncology
2018English

Expression of Protein Tyrosine Kinase 6 (PTK6) in Nonsmall Cell Lung Cancer and Their Clinical and Prognostic Significance

OncoTargets and Therapy
OncologyPharmacology
2013English

Cdk4/6 Inhibitors and Overall Survival: Power of First-Line Trials in Metastatic Breast Cancer

npj Breast Cancer
OncologyRadiologyNuclear MedicinePharmacologyImaging
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy